View of GLYCEMIC CONTROL AND BODY WEIGHT EFFECTS OF SGLT2 INHIBITORS (EMPAGLIFLOZIN 25 MG, EMPAGLIFLOZIN 12.5 MG AND DAPAGLIFLOZIN 10 MG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

Return to Article Details GLYCEMIC CONTROL AND BODY WEIGHT EFFECTS OF SGLT2 INHIBITORS (EMPAGLIFLOZIN 25 MG, EMPAGLIFLOZIN 12.5 MG AND DAPAGLIFLOZIN 10 MG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS Download Download PDF